Aducanumab

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...

Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis.  Ahead of the Dec. 5 presentation of aducanumab data at the Clinical Trials on Alzheimer'...

Biotech company Biogen Inc (NASDAQ: BIIB)'s once-failed Alzheimer's drug, aducanumab, re-emerged Oct. 22, and this creates a path for the stock to double in size, according to CNBC's Jim Cramer. What Happened Biogen resumed testing aducanumab, and results from a larger dataset in...

Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's drug aducanumab, which the company had written off back in March. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Underweight rating on...

Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...

Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...

Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...

Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...

Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

H.C. Wainwright said it is not surprised by Eli Lilly and Co (NYSE: LLY)’s announcement of solanezumab failing to slow the cognitive decline in Alzheimer’s Disease patients. The news is also said to be a negative for Biogen Inc (NASDAQ: BIIB), which is testing its own Alzheimer's...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...